These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. 5-ASA therapy and renal function in inflammatory bowel disease. Siveke JT; Egert J; Sitter T; Schiemann U; Walcher P; Török HP; Glas J; Folwaczny C Am J Gastroenterol; 2005 Feb; 100(2):501. PubMed ID: 15667517 [No Abstract] [Full Text] [Related]
6. [Is the lung a target organ in inflammatory bowel disease?]. Marvisi M; Fornasari G Recenti Prog Med; 2001 Dec; 92(12):774-7. PubMed ID: 11822102 [TBL] [Abstract][Full Text] [Related]
7. [Aminosalicylates in the treatment of idiopathic inflammatory bowel disease]. Lukás K Vnitr Lek; 1996 Feb; 42(2):117-9. PubMed ID: 8686186 [No Abstract] [Full Text] [Related]
8. Role of 5-aminosalicylate in preventing colorectal cancer. Riyaz S; Hamlin J; Everett S Am J Gastroenterol; 2011 Sep; 106(9):1720-1; author reply 1721-2. PubMed ID: 21897414 [No Abstract] [Full Text] [Related]
9. Renal tubular damage: an extraintestinal manifestation of chronic inflammatory bowel disease. Kreisel W; Wolf LM; Grotz W; Grieshaber M Eur J Gastroenterol Hepatol; 1996 May; 8(5):461-8. PubMed ID: 8804875 [TBL] [Abstract][Full Text] [Related]
12. Mesalazine-associated acute tubulointerstitial nephritis in a patient with spondylarthropathy. Sari I; Birlik M; Cavdar C; Sarioglu S; Akpinar H; Onen F; Akkoc N N Z Med J; 2005 Sep; 118(1222):U1662. PubMed ID: 16222356 [No Abstract] [Full Text] [Related]
13. Estimating the economic burden of inflammatory bowel disease in Canada: physician office visits and mesalamine prescriptions dispensed as surrogate markers. Wong VK; Lee TK; Yoshida EM Am J Gastroenterol; 2007 Nov; 102(11):2602-3; author reply 2603-4. PubMed ID: 17958766 [No Abstract] [Full Text] [Related]
14. Management of inflammatory bowel disease during pregnancy and nursing. Friedman S Semin Gastrointest Dis; 2001 Oct; 12(4):245-52. PubMed ID: 11726078 [TBL] [Abstract][Full Text] [Related]
15. Pancreatitis in inflammatory bowel diseases. Pitchumoni CS; Rubin A; Das K J Clin Gastroenterol; 2010 Apr; 44(4):246-53. PubMed ID: 20087199 [TBL] [Abstract][Full Text] [Related]
16. Drug therapy: dose-response relationship of oral mesalazine in inflammatory bowel disease. Mulder CJ; van den Hazel SJ Mediators Inflamm; 1998; 7(3):135-6. PubMed ID: 9705596 [TBL] [Abstract][Full Text] [Related]
17. Mesenteric ischemia is a cause of resistance to treatment in IBD. Ibiş M; Ataseven H; Basar O; Yüksel I; Ulker A Inflamm Bowel Dis; 2009 Aug; 15(8):1129-30. PubMed ID: 18951366 [No Abstract] [Full Text] [Related]
19. Macroscopic and histopathological examination of the gastric mucosa in dogs with inflammatory bowel disease (IBD) treated with mesalazine. Rychlik A; Nieradka R; Kander M; Depta A Pol J Vet Sci; 2009; 12(2):217-23. PubMed ID: 19645352 [TBL] [Abstract][Full Text] [Related]